Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis

M. Zlatev Ionescu, O. Nicolaescu, M. Nica, A. M. Petrescu, C. Calomfirescu, E. Ceausu, P. I. Calistru (Bucarest, Romania)

Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Session: Mechanisms of respiratory infections: interaction between the pathogen and the host
Session type: Thematic Poster Session
Number: 2290
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Zlatev Ionescu, O. Nicolaescu, M. Nica, A. M. Petrescu, C. Calomfirescu, E. Ceausu, P. I. Calistru (Bucarest, Romania). Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis. Eur Respir J 2008; 32: Suppl. 52, 2290

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011


Pseudomonas aeruginosa infections
Source: Respipedia Article
Year: 2018

Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016


Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 379s
Year: 2002

Fosfomycin for pseudomonas related exacerbations of cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008


Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis
Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017
Year: 2018



Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015


The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020


Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006



Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012



Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015

Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005

Long term treatment with azithromycin in chronic respiratory infections with pseudomonas aeruginosa
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003



Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 541s
Year: 2001

Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013


The efficacy of early eradication therapy in prevention of chronic pseudomonas aeruginosa infection in cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 486s
Year: 2006

Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis
Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017
Year: 2017